Health

Burkitt Lymphoma (BL) Therapeutics Market : Emerging Trends, Business Growth Opportunities, Major Driving Factors

Press Release

Burkitt lymphoma (BL) may be defined as an aggressive rare disorder that constitutes approximately 1% to 2% of all non-Hodgkin lymphomas. Burkitt lymphoma is known as one of the most aggressive forms of lymphoma, with a doubling time of approximately 24 hours. The term was coined after an Irish surgeon named Denis Burkitt, who first described the lymphoma in 1958, and was the first to successfully compile description of significant number of cases with the disorder. A range of intensive therapy regimen is available to choose from which depends upon local practice. The CODOX-M/IVAC is the most commonly administered regimen, first introduced as pediatric regimen in 1980 by Magrath et.al.

View Report: https://www.transparencymarketresearch.com/burkitt-lymphoma-therapeutics-market.html

Various regimen for Burkitt lymphoma (BL) are R-CODOX-M/IVAC regimen, BFM/GMALL/NHL regimen, Hyper-CVAD regimen, CALGB and LMB regimen, DA-EPOCH-R regimen, and other high-intensive regimens. Burkitt lymphoma is represented by three clinical sub-types: endemic Burkitt lymphoma (eBL), immunodeficiency-associated Burkitt lymphoma (iBL), and sporadic (sBL). These clinical sub-types share similar morphological and immunophenotypic features, while conform largely with respect to genetic makeup, and differ in exhibiting few clinical features as well as incidence pattern. Sporadic Burkitt lymphoma (sBL) is a rare disorder generally affecting all age groups. It accounts for approximately 1% of adult lymphomas and reported in areas lacking endemic malaria. Endemic Burkitt lymphoma (eBL) is predominantly a pediatric disease or disorder, accounting for about 30% to 50% of pediatric cancer in regions with holoendemic malaria. Endemic Burkitt lymphoma (eBL) clinically differs by affecting facial bones especially the jaw. Immunodeficiency-associated Burkitt lymphoma (iBL) accounts for 10% to 40% of all HIV (Human Immunodeficiency Virus) associated lymphomas and was the first to be recognized in HIV setting.

The CODOX-M/IVAC regimen includes cytarabine, cyclophosphamide, doxorubicin, etoposide, high-dose cytarabine, IT methotrexate, leucovorin, vincristine/ifosfamide. BFM/GMALL/NHL regimen generally consists of pre-phase treatment with prednisone and cyclophosphamide, which is then commenced by alternating chemotherapy with six cycles including doxorubicin, dexamethasone, ifosfamide, high-dose methotrexate, teniposide, cytarabine, and vincristine.

Request a Brochure of the Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=39413

It also includes triple IT therapy with cytarabine, dexamethasone, and methotrexate. Hyper-CVAD regimen which was initially developed for acute lymphoblastic leukemia includes four cycles of hyperfractionated cyclophosphamide, dexamethasone, vincristine, and doxorubicin. CALGB and LMB regimens utilize prednisone and cyclophosphamide as a pre-phase cycle, followed by alternating chemotherapy cycles depending upon the risk. DA-EPOCH-R regimen consists of different approach with low concentration chemotherapy agents being exposed for long period of time as compared to that of other high-intensive regimen, comprising infusional EPOCH (cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone). This regimen is specifically used in order to provide continuous exposure of cytotoxic agents to tumor cells and to bring about decrease in toxicity. Many variations of short-cycle, high intensive regimens are being developed and used in addition to these regimens.

The global Burkitt lymphoma (BL) therapeutics market can be segmented based on clinical type, drug therapy regimen, distribution channel, and region. In terms of clinical type, the market can be classified into endemic BL (eBL), immunodeficiency-associated BL (idBL), and sporadic variant (sBL). Based on drug therapy regimen, the global Burkitt lymphoma (BL) therapeutics market can be categorized into R-CODOX-M/IVAC regimen, BFM/GMALL/NHL regimen, Hyper-CVAD regimen, CALGB and LMB regimen, DA-EPOCH-R, and other high-intensive regimens. In terms of distribution channel, the market can be divided into drug stores, hospital pharmacy, online pharmacy, retail pharmacy, and others.

Request TOC @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=39413

In terms of region, the global Burkitt lymphoma (BL) therapeutics market can be segmented into Asia Pacific, Europe, Middle East & Africa, North America, and Latin America.

Key players in the global Burkitt lymphoma (BL) therapeutics market are Bedford Laboratories, Sun Pharma, Seattle Genetics, Inc., Sanofi, Mayo Clinic, Pfizer, Inc., Merck KGaA, and Cellerant Therapeutics, Inc., among others.

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

Contact Us

Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: [email protected]
Website: https://www.transparencymarketresearch.com

RSS news